Inactive Instrument

DICE THER

Equities

DICE

US23345J1043

DICE Therapeutics, Inc. has completed an IPO in the amount of $204 million.

September 14, 2021 at 12:00 am EDT

DICE Therapeutics, Inc. has completed an IPO in the amount of $204 million.

Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 12,000,000
PriceRange: $17
Discount Per Security: $1.19

Transaction Features: Sponsor Backed Offering

Latest news about DICE THER

S&P 500 Edges Down Weekly as US Consumer Prices Moved Modestly Higher in July, Technology, Materials Weigh	23-08-11	MT
Global markets live: Allianz, Generali, Sony, Disney, Alibaba...	23-08-10
Trending : Lilly Gets Price Target Increases, Closes DICE Purchase	23-08-09	DJ
Eli Lilly Completes Acquisition of DICE Therapeutics	23-08-09	MT
Eli Lilly Wraps Up Acquisition of Dice Therapeutics	23-08-09	MT
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from NASDAQ Composite Index	23-08-09	CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from S&P Pharmaceuticals Select Industry Index	23-08-09	CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from S&P Global BMI Index	23-08-09	CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from S&P TMI Index	23-08-09	CI
Eli Lilly and Company completed the acquisition of DICE Therapeutics, Inc. from a group of shareholders.	23-08-08	CI
DICE Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from NASDAQ Biotechnology Index	23-07-28	CI
Eli Lilly Extends Tender Offer to Acquire DICE Therapeutics to Aug. 9	23-07-25	MT
Eli Lilly Extends $2.4 Billion Tender Offer to Buy DICE Therapeutics	23-07-25	MT
MoonLake Immunotherapeutics explores sale-sources	23-07-14	RE
North American Morning Briefing : Stock Futures -2-	23-06-27	DJ
Needham Downgrades DICE Therapeutics to Hold From Buy	23-06-23	MT
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from Russell 3000E Index	23-06-23	CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from Russell Microcap Index	23-06-23	CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from Russell Microcap Value Index	23-06-23	CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from Russell 3000E Value Index	23-06-23	CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) added to Russell 3000E Growth Index	23-06-23	CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) added to Russell 2500 Growth Index	23-06-23	CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) added to Russell 3000 Growth Index	23-06-23	CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) added to Russell Small Cap Comp Growth Index	23-06-23	CI

Chart DICE THER

Duration

Period

More charts

Company Profile

DICE Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing oral therapeutics against well-validated targets in immunology. The Company's platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The Company's therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The Company is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.

Sector

More about the company